Care Coordination and Transition Strategies for CAR-T Therapy
Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.
EP: 1.Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma
EP: 2.Patient Selection and Referral Eligibility for CAR-T Therapy
EP: 3.Understanding the CAR-T Treatment Process
EP: 4.CAR-T Therapy: Approach to Bridging
EP: 5.Care Coordination and Transition Strategies for CAR-T Therapy
EP: 6.CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
EP: 7.Key Takeaways in CAR-T Therapy for Multiple Myeloma
Video content above is prompted by the following:
- Describe your institution’s approach to the co-management and co-monitoring of patients receiving CAR-T therapy, particularly in the transition back to the community setting.
- Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for CAR-T patients?
- What are the most common challenges you have encountered in the CAR-T referral process, and how have you addressed them at your institution?
- What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR-T therapy?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
